Microbiologics expands viral capabilities for SARS-CoV-2

Create PDF

September 2020—Microbiologics has expanded its custom virology solutions in its renovated virology services lab to include biosafety level 3 antiviral services. With these new capabilities, the company has launched a menu of cell-based services for SARS-CoV-2 to assist assay developers, evaluate therapeutic solutions and vaccines, and provide inactivated intact virus to researchers and diagnostic companies. It has also expanded its viral capabilities to include reverse genetics systems to create recombinant viruses and has increased its in vitro assay capabilities, including cytopathic effect screening, hemagglutination-inhibition testing, neutralization assays, and yield-reduction assays.